Blood aldosterone level in various types of atrial fibrillation
https://doi.org/10.15829/1728-8800-2016-1-40-44
Abstract
Aim. To analyse the aldosterone level in the blood of patients with different kinds of atrial fibrillation (AF) and sinus rhythm.
Material and methods. Totally, 130 patients included (main group) with AF of non-valvular origin. Of those 40 (30,8%) had permanent, 50 (38,4%) — persistent, and 40 (30,8%) — paroxysmal type of atrial fibrillation. The controls consisted of 40 patients with cardiovascular pathology not having anamnesis of AF. Aldosterone levels were measured by immune-enzyme assay. In paroxysmal and persistent AF the measurement was done before returning to sinus rhythm. Reference ranges for aldosterone were 40-160 pg/ml.
Results. Aldosterone level in blood was significantly higher in the main group comparing to controls — mean 141,5±41,8 pg/ml vs 105,0±33,1 pg/ml (р<0,001). The highest level had persisting and paroxysmal AF patients and a little lower in permanent AF patients. Prevalence of hyperaldosteronemia among all patients of the main group was significantly higher comparing to controls, and reached 32,3% and 7,5%, resp., (χ2=8,44, p=0,004), however in multiple analysis the significant differences were revealed only among those with paroxysmal type (47,5%) and sinus rhythm patients.
Conclusion. In AF patients aldosterone level is significantly higher comparing to sinus rhythm patients. In addition, the level is significantly higher in paroxysmal and persistent comparing to permanent type.
About the Authors
N. T. Vatutin
M. Gorky Donetsk National Medical University. Donetsk;
Ukraine
Ukraine
A. N. Shevelok
M. Gorky Donetsk National Medical University. Donetsk;
Ukraine
Ukraine
I. N. Kravchenko
V. K. Gusak Institute of Urgent and Recovery Surgery. Donetsk, Ukraine
Ukraine
Ukraine
References
1. January CT, Wann ST, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. A report of the American College of Cardiology. American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society: Executive summary. JACC; 2014: DOI:10.1016/j.jacc.2014.03.021.
2. Sulimov VA, Golicyn SP, Panchenko EP. Diagnosis and treatment of atrial fibrillation. Recommendations of Russian Society of Cardiology and Association of Cardiovascular Surgeons 2012. Russ J Cardiol 2013; 4 (102): 5-92, Suppl. 3. Russian (Сулимов В.А., Голицын С.П., Панченко Е.П. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ 2012г. Российский кардиологический журнал 2013; 4 (102): 5-92, Приложение 3).
3. Yongjun Q, Ying L, Hong T, et al. Circulating and local renin-angiotensin-aldosteron system express differently in atrial fibrillation patients with different types of mitral valvular disease. J Ren-Angioten-Aldoster Syst 2013; 14: 204-11.
4. Reil J-C, Hohl M, Selejan S, et al. Aldosterone promotes atrial fibrillation. Eur Heart J 2012; 33: 2098-108.
5. Khatib R, Joseph P, Briel M, et al. Blockade of the renin-angiotensin-aldosterone system for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials. Int J Cardiol 2013; 165(1): 17-24.
6. Vatutin NT, Shevelok AN, Degtyareva AE, el al. The role of hyperaldosteronism and aldosterone antagonists in resistant arterial hypertension. J National academy of medical science of Ukraine 2014; 1(20): 43-52. Russian (Ватутин Н.Т., Шевелёк А.Н., Дегтярева А.Э. и др. Роль гиперальдостеронизма и перспективы применения антагонистов альдостерона при резистентной артериальной гипертензии. Журнал национальной академии медицинских наук Украины 2014; 1(20):43-52).
7. Zennaro MC, Rickard AJ, Boulkroun S. Genetics of mineralocorticoid excess: an update for clinicians. Eur J Endocrinol 2013; 169 (1): 15-25.
8. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. JACC 2005; 45: 1243-8.
9. Vaidya A, Halperin F, Alexander EK, et al. Hyperaldosteronism. South Dartmouth (MA): MDText.com, Inc.; 2000. pp. 126-8.
10. Harvey AM. Hyperaldosteronism: diagnosis, lateralization, and treatment. Surg Clin North Am 2014; 94(3): 643-56.
11. Zhao J, Li J, Li Y, et al. Effects of spironolactone on atrial structural remodeling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br J Pharmacol 2010; 159: 1584-94.
12. Reil J-C, Hohl M, Selejan S, et al. Aldosterone promotes atrial fibrillation. Eur Heart J 2012; 33: 2098-108.
13. Goette A, Hoffmanns P, Enayati W, et al. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol 2001; 88: 906-9.
Review
For citations:
Vatutin N.T., Shevelok A.N., Kravchenko I.N. Blood aldosterone level in various types of atrial fibrillation. Cardiovascular Therapy and Prevention. 2016;15(1):40-44. (In Russ.) https://doi.org/10.15829/1728-8800-2016-1-40-44
Views:
928
Email this article 
